Anixa Biosciences (CY71) Stock Statistics & Valuation Metrics
Total Valuation
Anixa Biosciences has a market cap or net worth of EUR 101.72M. The enterprise value is EUR 90.23T.
- Market Cap
- EUR 101.72M
- Enterprise Value
- EUR 90.23T
Share Statistics
Anixa Biosciences has 34,763,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 34,763,800
- Owned by Insiders
- 5.68%
- Owned by Institutions
- 9.11%
Financial Efficiency
Anixa Biosciences’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -82.67%.
- Return on Equity (ROE)
- -0.72
- Return on Assets (ROA)
- -0.68
- Return on Invested Capital (ROIC)
- -82.67%
- Return on Capital Employed (ROCE)
- -0.83
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.73M
- Employee Count
- 4
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Anixa Biosciences is -9.93. Anixa Biosciences’s PEG ratio is 0.01.
- PE Ratio
- -9.93
- PS Ratio
- 0.00
- PB Ratio
- 7.16
- Price to FCF
- -14.28
- Price to Operating Cash Flow
- -14.04
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Anixa Biosciences had revenue of 0 and earned -10.93M in profits. Earnings per share was -0.34.
- Revenue
- 0
- Gross Profit
- -36.00K
- Operating Income
- -11.70M
- Pretax Income
- -11.03M
- Net Income
- -10.93M
- EBITDA
- -10.99M
- Earnings Per Share (EPS)
- -0.34
Cash Flow
In the last 12 months, operating cash flow was -7.38M and capital expenditures 0, giving a free cash flow of -7.38M billion.
- Operating Cash Flow
- -7.38M
- Free Cash Flow
- -7.38M
- Free Cash Flow per Share
- -0.22
Dividends & Yields
Anixa Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.00%
- Earnings Yield
- -10.06%
Stock Price Statistics
- Beta
- 0.62
- 52-Week Price Change
- -19.91%
- 50-Day Moving Average
- 2.57
- 200-Day Moving Average
- 2.53
- Relative Strength Index (RSI)
- 56.83
- Average Volume (3m)
- 934
Important Dates
Anixa Biosciences upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Mar 08, 2024
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Anixa Biosciences as a current ratio of 8.08, with Debt / Equity ratio of 1.35%
- Current Ratio
- 8.08
- Quick Ratio
- 8.08
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.09
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Anixa Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Anixa Biosciences EV to EBITDA ratio is -9.87, with an EV/FCF ratio of -14.11.
- EV to Sales
- 0.00
- EV to EBITDA
- -9.87
- EV to Free Cash Flow
- -14.11
- EV to Operating Cash Flow
- -14.11
Balance Sheet
Anixa Biosciences has EUR 13.86M in cash and marketable securities with EUR 174.00K in debt, giving a net cash position of EUR 13.69M billion.
- Cash & Marketable Securities
- EUR 13.86M
- Total Debt
- EUR 174.00K
- Net Cash
- EUR 13.69M
- Net Cash Per Share
- EUR 0.39
- Tangible Book Value Per Share
- EUR 0.39
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Anixa Biosciences is EUR 8.94, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 8.94
- Price Target Upside
- 224.54% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 15.83%
Scores
- Smart Score
- 5
- AI Score
- ―
